Skip to main content

Amoxicillin/clarithromycin/lansoprazole Disease Interactions

There are 14 disease interactions with amoxicillin / clarithromycin / lansoprazole.

Major

Antibiotics (applies to amoxicillin/clarithromycin/lansoprazole) colitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious), Colitis/Enteritis (Noninfectious)

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

References

  1. (2002) "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories
  2. (2002) "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome
  3. (2002) "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome
  4. (2002) "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn
  5. (2002) "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals
  6. (2002) "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals
  7. (2001) "Product Information. Amoxil (amoxicillin)." SmithKline Beecham
  8. (2001) "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals
  9. (2001) "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis
  10. (2001) "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn
  11. (2003) "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc
  12. (2004) "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals
  13. (2007) "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical
  14. (2009) "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc
  15. (2009) "Product Information. Vibativ (telavancin)." Theravance Inc
  16. (2010) "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals
  17. (2022) "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc
  18. (2014) "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.
  19. (2014) "Product Information. Orbactiv (oritavancin)." The Medicines Company
  20. (2017) "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions
  21. (2017) "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.
  22. (2022) "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC
  23. (2018) "Product Information. Zemdri (plazomicin)." Achaogen
  24. (2018) "Product Information. Seysara (sarecycline)." Allergan Inc
  25. (2018) "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.
  26. (2018) "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.
  27. (2019) "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc
  28. (2019) "Product Information. Biaxin (clarithromycin)." AbbVie US LLC, SUPPL-61
  29. (2021) "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group, LAB-0372-7.0
  30. (2018) "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals, SUPPL-74
  31. (2020) "Product Information. Priftin (rifapentine)." sanofi-aventis, SUPPL-18
  32. (2021) "Product Information. Xerava (eravacycline)." Tetraphase Pharmaceuticals, Inc
  33. (2023) "Product Information. Xacduro (durlobactam-sulbactam)." La Jolla Pharmaceutical
  34. (2024) "Product Information. Exblifep (cefepime-enmetazobactam)." Allecra Therapeutics
  35. (2021) "Product Information. Maxipime (cefepime)." Hospira Inc, SUPPL-46
View all 35 references
Major

PPIs (applies to amoxicillin/clarithromycin/lansoprazole) C. diff

Major Potential Hazard, Moderate plausibility. Applicable conditions: Pseudomembranous Colitis, Diarrhea

Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve. It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

References

  1. (2022) "Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc
  2. (2001) "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc
  3. (2001) "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals
  4. (2001) "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories
  5. "Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories
  6. (2009) "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America
  7. (2014) "Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals
  8. (2014) "Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals
View all 8 references
Moderate

Aminopenicillins (applies to amoxicillin/clarithromycin/lansoprazole) mononucleosis

Moderate Potential Hazard, Moderate plausibility.

Patients with mononucleosis treated with an aminopenicillin antibiotic, may develop a pruritic erythematous maculopapular skin rash. The rash is usually self-limiting and resolves within days of discontinuing the offending agent. An altered drug metabolism or an immune-mediated process unrelated to drug hypersensitivity has been proposed as the underlying mechanism. Therapy with aminopenicillin antibiotics should not be administered in patients with mononucleosis.

References

  1. "Product Information. Polycillin-PRB (ampicillin-probenecid)." Apothecon Inc
  2. (2002) "Product Information. Spectrobid (bacampicillin)." Roerig Division
  3. (2001) "Product Information. Amoxil (amoxicillin)." SmithKline Beecham
Moderate

Amoxicillin (applies to amoxicillin/clarithromycin/lansoprazole) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using Clinitest®, Benedict's Solution or Fehling's Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix®) be used.

References

  1. (2001) "Product Information. Amoxil (amoxicillin)." SmithKline Beecham
Moderate

Amoxicillin (applies to amoxicillin/clarithromycin/lansoprazole) PKU

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Phenylketonuria

Some amoxicillin chewable tablets and suspensions products contain phenylalanine. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

References

  1. (2002) "Product Information. Augmentin (amoxicillin-clavulanate)." SmithKline Beecham
Moderate

Beta-lactams (oral) (applies to amoxicillin/clarithromycin/lansoprazole) renal dysfunction

Moderate Potential Hazard, High plausibility.

Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function. Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.

References

  1. Bergan T (1978) "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother, 13, p. 971-4
  2. Ehrnebo M, Nilsson SO, Boreus LO (1979) "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm, 7, p. 429-51
  3. Humbert G, Spyker DA, Fillastre JP, Leroy A (1979) "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother, 15, p. 28-33
  4. Bloch R, Szwed JJ, Sloan RS, Luft FC (1977) "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother, 12, p. 730-2
  5. Santoro J, Agarwal BN, Martinelli R, et al. (1978) "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother, 13, p. 951-4
  6. Spyker DA, Thomas BL, Sande MA, Bolton WK (1978) "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother, 14, p. 172-7
  7. Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E (1979) "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother, 5, p. 465-70
  8. Fillastre JP, Leroy A, Humbert G, Godin M (1980) "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother, 6, p. 155-6
  9. Berman SJ, Boughton WH, Sugihara JG, et al. (1978) "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother, 14, p. 281-3
  10. Spyker DA, Gober LL, Scheld WM, et al. (1982) "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother, 21, p. 278-81
  11. Pommer W, Krause PH, Berg PA, et al. (1986) "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr, 64, p. 290-3
  12. Guay DR, Meatherall RC, Harding GK, Brown GR (1986) "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother, 30, p. 485-90
  13. Dhib M, Moulin B, Leroy A, et al. (1991) "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol, 41, p. 579-83
  14. Shyu WC, Pittman KA, Wilber RB, et al. (1991) "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol, 31, p. 362-71
  15. Humbert G, Leroy A, Fillastre JP, Godin M (1979) "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy, 25, p. 189-95
  16. Leroy A, Humbert G, Godin M, Fillastre JP (1982) "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother, 10, p. 39-46
  17. Kabins SA, Kelner B, Walton E, Goldstein E (1970) "Cephalexin therapy as related to renal function." Am J Med Sci, 259, p. 133-42
  18. Kunin CM, Finkelberg Z (1970) "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med, 72, p. 349-56
  19. Yamasaku F, Tsuchida R, Usuda Y (1970) "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J, Suppl, p. 57-9
  20. Bailey RR, Gower PE, Dash CH (1970) "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J, 46, p. 60-4
  21. Regamey C, Humair L (1971) "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J, 47 Supp), p. 69-77
  22. Reisberg BE, Mandelbaum JM (1971) "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun, 3, p. 540-3
  23. Kirby WM, de Maine JB, Serrill WS (1971) "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J, 47 Suppl, p. 41-6
  24. Brogard JM, Pinget M, Dorner M, Lavillaureix J (1975) "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol, 15, p. 666-73
  25. Chow M, Quintiliani R, Cunha BA, et al. (1979) "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol, 19, p. 185-94
  26. Finkelstein ER, Quintiliani R, Nightingale CH (1978) "Pharmacokinetics of oral cephalosporins." J Pediatr, 93, p. 902
  27. Andriole VT (1978) "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis, 137, s88-99
  28. Hori R, Okumura K, Nihira H, et al. (1985) "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther, 38, p. 290-5
  29. St Peter JV, Borin MT, Hughes GS, et al. (1992) "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother, 36, p. 126-31
  30. Gibaldi M, Perrier D (1972) "Drug distribution and renal failure." J Clin Pharmacol, 12, p. 201-4
  31. Hoffman TA, Cestero R, Bullock WE (1970) "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med, 73, p. 173-8
  32. Latos DL, Bryan CS, Stone WJ (1975) "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther, 17, p. 692-700
  33. Arancibia A, Droguett MT, Fuentes G, et al. (1982) "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol, 20, p. 447-53
  34. Sjovall J, Westerlund D, Alvan G (1985) "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol, 19, p. 191-201
  35. Jackson EA, McLeod DC (1974) "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm, 31, p. 36-52
  36. Bailey RR, Eastwood JB, Vaughan RB (1972) "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J, 48, p. 422-5
  37. Nelson JD, Reimold EW (1973) "Carbenicillin pharmacokinetics in an anephric patient." Lancet, 1, p. 486-7
  38. Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H (1977) "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy, 23, p. 299-308
  39. Hoffler D, Koeppe P, Corcilius M, Przyklink A (1990) "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection, 18, p. 157-62
  40. Yamasaku F, Tsuchida R, Usada Y (1970) "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J, Suppl, p. 57-9
  41. Standiford HC, Jordan MC, Kirby WM (1970) "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis, 122, s9-13
  42. Andriole VT (1978) "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis, 137, s88-97
  43. Schwinghammer TL, Norden CW, Gill E (1990) "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol, 30, p. 893-9
  44. Solomon AE, Briggs JD (1975) "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol, 2, p. 443-8
  45. Neu HC (1981) "The pharmacokinetics of bacampicillin." Rev Infect Dis, 3, p. 110-6
  46. Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G (1981) "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther, 4, p. 32-42
  47. DeSante KA, Zeckel ML (1992) "Pharmacokinetic profile of loracarbef." Am J Med, 92, s16-9
  48. "Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.
  49. (2002) "Product Information. Spectrobid (bacampicillin)." Roerig Division
  50. (2002) "Product Information. Geocillin (carbenicillin)." Roerig Division
  51. (2002) "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company
  52. (2002) "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb
  53. (2002) "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc
  54. (2002) "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn
  55. (2002) "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb
  56. (2002) "Product Information. Keflex (cephalexin)." Dista Products Company
  57. (2002) "Product Information. Velosef (cephradine)." Apothecon Inc
  58. (2002) "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company
  59. Therasse DG, Farlow DS, Davidson RL, et al. (1993) "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther, 54, p. 311-6
  60. Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE (1994) "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos, 22, p. 447-50
  61. Hyslop DL (1988) "Cefaclor safety profile: a ten-year review." Clin Ther, 11 Suppl A, p. 83-94
  62. (2001) "Product Information. Amoxil (amoxicillin)." SmithKline Beecham
  63. (2001) "Product Information. Cedax (ceftibuten)." Schering-Plough
  64. Nix DE, Symonds WT, Hyatt JM, et al. (1997) "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy, 17, p. 121-5
  65. (2001) "Product Information. Omnicef (cefdinir)." Parke-Davis
  66. Guay DRP (1997) "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother, 31, p. 1022-33
  67. (2001) "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc
View all 67 references
Moderate

Clarithromycin (applies to amoxicillin/clarithromycin/lansoprazole) hepatotoxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin. The hepatic dysfunction may be severe but in most cases is reversible. Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications. Caution and monitoring is advised if using this drug in patients with hepatic impairment. Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen). The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.

References

  1. (2002) "Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical
  2. (2022) "Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc
Moderate

Clarithromycin (applies to amoxicillin/clarithromycin/lansoprazole) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Clarithromycin is primarily eliminated by the kidney and liver. A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min). Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease. Monitoring is advised.

References

  1. (2002) "Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical
Moderate

Lansoprazole (applies to amoxicillin/clarithromycin/lansoprazole) liver disease

Moderate Potential Hazard, Moderate plausibility.

Lansoprazole is primarily metabolized by the liver. Although the drug is generally well-tolerated, dosage adjustments with cautious titration should be considered in patients with severe hepatic impairment.

References

  1. Spencer CM, Faulds D (1994) "Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid- related disorders." Drugs, 48, p. 404-30
  2. Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M (1993) "Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity." Eur J Clin Pharmacol, 45, p. 367-71
  3. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P (1995) "Oxidative metabolism of lansoprazole by human liver cytochromes P450." Mol Pharmacol, 47, p. 410-8
  4. (2001) "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc
View all 4 references
Moderate

Macrolide antibiotics (applies to amoxicillin/clarithromycin/lansoprazole) myasthenia gravis

Moderate Potential Hazard, Moderate plausibility.

The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome. Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.

References

  1. (2019) "Product Information. Biaxin (clarithromycin)." AbbVie US LLC, SUPPL-61
  2. (2022) "Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group, LAB-0024-23.0
  3. (2021) "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group, LAB-0372-7.0
  4. (2018) "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals, SUPPL-74
View all 4 references
Moderate

Macrolide antibiotics (applies to amoxicillin/clarithromycin/lansoprazole) QT prolongation

Moderate Potential Hazard, High plausibility. Applicable conditions: Hypokalemia, Magnesium Imbalance, Arrhythmias

Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Clarithromycin and erythromycin should be avoided in: patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.

References

  1. (2019) "Product Information. Biaxin (clarithromycin)." AbbVie US LLC, SUPPL-61
  2. (2018) "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals, SUPPL-74
Moderate

Penicillins (applies to amoxicillin/clarithromycin/lansoprazole) hemodialysis

Moderate Potential Hazard, High plausibility.

Penicillin antibiotics (except for agents in the penicillinase-resistant class) are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.

References

  1. Giron JA, Meyers BR, Hirschman SZ, Srulevitch E (1981) "Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother, 19, p. 279-83
  2. Heim KL (1985) "The effect of hemodialysis on piperacillin pharmacokinetics." Drug Intell Clin Pharm, 19, p. 455
  3. Francke EL, Appel GB, Neu HC (1979) "Kinetics of intravenous amoxicillin in patients on long-term dialysis." Clin Pharmacol Ther, 26, p. 31-5
  4. Slaughter RL, Kohli R, Brass C (1984) "Effects of hemodialysis on the pharmacokinetics of amoxicillin/clavulanic acid combination." Ther Drug Monit, 6, p. 424-7
  5. Janicke DM, Mangione A, Schultz RW, Jusko WJ (1981) "Mezlocillin disposition in chronic hemodialysis patients." Antimicrob Agents Chemother, 20, p. 590-4
  6. Kampf D, Schurig R, Weihermuller K, Forster D (1980) "Effects of impaired renal function hemodialysis and peritoneal dialysis on the pharmacokinetics of mezlocillin." Antimicrob Agents Chemother, 18, p. 81-7
  7. Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE (1988) "Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of augmentin." Br J Clin Pharmacol, 26, p. 385-90
  8. Francke E, Mehta S, Neu HC, Appel GB (1979) "Kinetics of intravenous mezlocillin in chronic hemodialysis patients." Clin Pharmacol Ther, 26, p. 228-31
  9. Thorsteinsson SB, Steingrimsson O, Asmundsson P, Bergan T (1981) "Pharmacokinetics of mezlocillin during haemodialysis." Scand J Infect Dis, 29, p. 59-63
  10. Wise R, Reeves DS, Parker AS (1974) "Administration of ticarcillin, a new antipseudomonal antibiotic, in patients undergoing dialysis." Antimicrob Agents Chemother, 5, p. 119-20
  11. Brogard JM, Comte F, Spach MO, Lavillaureix J (1982) "Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function." Chemotherapy, 28, p. 318-26
  12. Oe PL, Simonian S, Verhoef J (1973) "Pharmacokinetics of the new penicillins." Chemotherapy, 19, p. 279-88
  13. Reitberg DP, Marble DA, Schultz RW, Whall TJ, Schentag JJ (1988) "Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother, 32, p. 503-9
  14. Blum RA, Kohli RK, Harrison NJ, Schentag JJ (1989) "Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother, 33, p. 1470-6
  15. Rho JP, Jones A, Wood M, et al. (1989) "Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects." J Antimicrob Chemother, 24, p. 573-80
  16. "Product Information. Polycillin-PRB (ampicillin-probenecid)." Apothecon Inc
  17. (2002) "Product Information. Spectrobid (bacampicillin)." Roerig Division
  18. (2002) "Product Information. Geocillin (carbenicillin)." Roerig Division
  19. (2002) "Product Information. Mezlin (mezlocillin)." Bayer
  20. (2001) "Product Information. Pfizerpen (penicillin)." Roerig Division
  21. (2001) "Product Information. Pipracil (piperacillin)." Lederle Laboratories
  22. (2001) "Product Information. Ticar (ticarcillin)." SmithKline Beecham
View all 22 references
Moderate

Proton pump inhibitors (applies to amoxicillin/clarithromycin/lansoprazole) bone fractures

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Osteoporosis

Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.

References

  1. (2001) "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc
  2. (2001) "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals
  3. (2001) "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals
  5. (2003) "Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc
  6. (2009) "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America
  7. (2023) "Product Information. Voquezna (vonoprazan)." Phathom Pharmaceuticals, Inc
View all 7 references
Moderate

Proton pump inhibitors (applies to amoxicillin/clarithromycin/lansoprazole) hypomagnesemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Magnesium Imbalance

Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy. Serious adverse events can include tetany, seizures, and arrhythmias. Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics). Regular monitoring is recommended.

References

  1. (2001) "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc
  2. (2001) "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals
  3. (2001) "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals
  5. (2003) "Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc
  6. (2009) "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America
View all 6 references

Amoxicillin/clarithromycin/lansoprazole drug interactions

There are 782 drug interactions with amoxicillin / clarithromycin / lansoprazole.

Amoxicillin/clarithromycin/lansoprazole alcohol/food interactions

There is 1 alcohol/food interaction with amoxicillin / clarithromycin / lansoprazole.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.